Cargando…
Ginsenoside Re Improves Inflammation and Fibrosis in Hepatic Tissue by Upregulating PPARγ Expression and Inhibiting Oxidative Stress in db/db Mice
Ginsenoside Re (Re) is the main component of “Zhenyuan Capsule” (ZYC), which was wildly used in clinic in China for adjunctive treatment of coronary heart disease (CHD) and type II diabetes (T2DM). Nonalcoholic fatty liver disease (NAFLD) is one of the most important complications of T2DM, as well a...
Autores principales: | Jiang, Yichuan, Sui, Dayun, Li, Min, Xu, Huali, Yu, Xiaofeng, Liu, Jinsha, Yu, Qian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8519719/ https://www.ncbi.nlm.nih.gov/pubmed/34659439 http://dx.doi.org/10.1155/2021/9003603 |
Ejemplares similares
-
Ginsenoside Rg3 has effects comparable to those of ginsenoside re on diabetic kidney disease prevention in db/db mice by regulating inflammation, fibrosis and PPARγ
por: Sui, Zhe, et al.
Publicado: (2023) -
Ginsenoside Rb1 ameliorates liver fat accumulation by upregulating perilipin expression in adipose tissue of db/db obese mice
por: Yu, Xizhong, et al.
Publicado: (2015) -
Ginsenoside Rg3 Alleviates ox-LDL Induced Endothelial Dysfunction and Prevents Atherosclerosis in ApoE(−/−) Mice by Regulating PPARγ/FAK Signaling Pathway
por: Geng, Jianan, et al.
Publicado: (2020) -
Ginsenoside Rg2 alleviates myocardial fibrosis by regulating TGF-β1/Smad signalling pathway
por: Wang, Quanwei, et al.
Publicado: (2021) -
Ginsenoside Rg3 Attenuates Angiotensin II-Mediated Renal Injury in Rats and Mice by Upregulating Angiotensin-Converting Enzyme 2 in the Renal Tissue
por: Liu, Hui, et al.
Publicado: (2019)